INT253819

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.40
First Reported 2008
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 6
Disease Relevance 0.34
Pain Relevance 3.49

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Cartpt) extracellular region (Cartpt)
Cartpt (Mus musculus)
Pain Link Frequency Relevance Heat
Cholecystokinin 576 100.00 Very High Very High Very High
antagonist 78 99.24 Very High Very High Very High
medulla 162 97.88 Very High Very High Very High
Kinase C 6 94.84 High High
Eae 78 90.72 High High
analgesia 12 88.88 High High
Locus ceruleus 6 59.88 Quite High
cocaine 18 50.00 Quite Low
Analgesic 6 29.04 Quite Low
Intracerebroventricular 6 25.28 Quite Low
Disease Link Frequency Relevance Heat
Ganglion Cysts 6 84.00 Quite High
Appetite Loss 6 64.40 Quite High
Anxiety Disorder 6 50.52 Quite High
Peripheral Arterial Disease 6 43.64 Quite Low
Body Weight 12 36.64 Quite Low
Aids-related Complex 30 31.56 Quite Low
Sleep Disorders 6 29.84 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Relationship between CCK and the CART peptide was documented also at pancreatic exocrine secretion of amylase where the stimulating effect of CART peptide was inhibited in vivo but not in vitro by CCK-A receptor antagonist devazepide [26].
Negative_regulation (effect) of CART peptide associated with antagonist and cholecystokinin
1) Confidence 0.40 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2587474 Disease Relevance 0.14 Pain Relevance 0.55
This pathway could contribute to the additive effect of CCK and CART peptide in the DMH.
Negative_regulation (effect) of CART peptide associated with cholecystokinin
2) Confidence 0.40 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2587474 Disease Relevance 0 Pain Relevance 0.75
A significant increase in Fos immunoreactivity was registered after application of CCK-8 (p < 0.01), CART(61-102) (p < 0.01), and parallel administration of CCK-8 and CART(61-102) (p < 0.01) in comparison with saline-treated mice (Fig. 3b, d).
Negative_regulation (application) of CART associated with cholecystokinin
3) Confidence 0.35 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2587474 Disease Relevance 0 Pain Relevance 0.46
Relationship between CCK and the CART peptide was documented also at pancreatic exocrine secretion of amylase where the stimulating effect of CART peptide was inhibited in vivo but not in vitro by CCK-A receptor antagonist devazepide [26].
Negative_regulation (documented) of CART peptide associated with antagonist and cholecystokinin
4) Confidence 0.35 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2587474 Disease Relevance 0.19 Pain Relevance 0.64
Similarly, the anorexigenic action of CART peptide in rats was prevented by GLP-1 receptor antagonist [29].
Negative_regulation (prevented) of CART peptide associated with antagonist
5) Confidence 0.35 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2587474 Disease Relevance 0 Pain Relevance 0.60
CCK-A receptor inactivation with its antagonist devazepide prevented the anorexigenic effect of CART(61-102) (0.1 and 0.5 ?
Negative_regulation (effect) of CART associated with antagonist and cholecystokinin
6) Confidence 0.35 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2587474 Disease Relevance 0 Pain Relevance 0.49

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox